MA42543A - Arn épitope peptidiques concatémériques - Google Patents

Arn épitope peptidiques concatémériques

Info

Publication number
MA42543A
MA42543A MA042543A MA42543A MA42543A MA 42543 A MA42543 A MA 42543A MA 042543 A MA042543 A MA 042543A MA 42543 A MA42543 A MA 42543A MA 42543 A MA42543 A MA 42543A
Authority
MA
Morocco
Prior art keywords
concatemeric
peptidic epitope
epitope rna
rna
peptidic
Prior art date
Application number
MA042543A
Other languages
English (en)
Inventor
Giuseppe Ciaramella
Eric Yi-Chun Huang
Nicholas Valiante
Tal Zaks
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA42543A publication Critical patent/MA42543A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111Immunoglobulin superfamily
    • A61K39/001114CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645Dendrimers; Multiple antigen peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042543A 2015-07-30 2016-07-29 Arn épitope peptidiques concatémériques MA42543A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199204P 2015-07-30 2015-07-30
US201562245145P 2015-10-22 2015-10-22
US201562247367P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
MA42543A true MA42543A (fr) 2018-06-06

Family

ID=57886863

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042543A MA42543A (fr) 2015-07-30 2016-07-29 Arn épitope peptidiques concatémériques

Country Status (5)

Country Link
US (2) US20190008938A1 (fr)
EP (1) EP3328394A4 (fr)
HK (1) HK1256498A1 (fr)
MA (1) MA42543A (fr)
WO (1) WO2017020026A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201710473VA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
EP3324979B1 (fr) * 2015-07-21 2022-10-12 ModernaTX, Inc. Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
CA3003090A1 (fr) * 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins anticancereux
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP4349405A3 (fr) 2015-10-22 2024-06-19 ModernaTX, Inc. Vaccins contre le virus respiratoire
WO2017070624A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins contre des maladies tropicales
CA3002912A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccins a base d'acide nucleique contre le virus varicelle-zona (vzv)
EP3964200A1 (fr) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
MA45051A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant la relaxine
EP4166666A1 (fr) 2016-09-14 2023-04-19 ModernaTX, Inc. Compositions d'arn à pureté élevée et leurs procédés de préparation
EP3528821A4 (fr) 2016-10-21 2020-07-01 ModernaTX, Inc. Vaccin contre le cytomégalovirus humain
AU2017347837A1 (en) * 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2018089851A2 (fr) 2016-11-11 2018-05-17 Modernatx, Inc. Vaccin antigrippal
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
US20190351039A1 (en) * 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110505877A (zh) * 2017-02-01 2019-11-26 摩登纳特斯有限公司 Rna癌症疫苗
EP3582790A4 (fr) 2017-02-16 2020-11-25 ModernaTX, Inc. Compositions immunogènes très puissantes
WO2018170256A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus de l'herpès simplex
WO2018170270A1 (fr) 2017-03-15 2018-09-20 Modernatx, Inc. Vaccin contre le virus varicelle-zona
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
EP3609534A4 (fr) 2017-03-15 2021-01-13 ModernaTX, Inc. Vaccin à large spectre contre le virus de la grippe
WO2018170347A1 (fr) 2017-03-17 2018-09-20 Modernatx, Inc. Vaccins à base d'arn contre des maladies zoonotiques
WO2018167320A1 (fr) * 2017-03-17 2018-09-20 Curevac Ag Vaccin à arn et inhibiteurs de points de contrôle immunitaires pour une thérapie anticancéreuse combinée
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
US11203629B2 (en) * 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
EP3638215A4 (fr) 2017-06-15 2021-03-24 Modernatx, Inc. Formulations d'arn
KR20200027499A (ko) * 2017-07-12 2020-03-12 노우스콤 아게 암 치료용 신생항원 백신 조성물
FI3652606T3 (fi) * 2017-07-12 2023-03-16 Nouscom Ag Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
MA49913A (fr) 2017-08-18 2021-05-05 Modernatx Inc Variants d'arn polymérase
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019148101A1 (fr) 2018-01-29 2019-08-01 Modernatx, Inc. Vaccins à base d'arn contre le vrs
WO2019227106A1 (fr) * 2018-05-25 2019-11-28 The Wistar Institute Néo-antigènes spécifiques d'une tumeur et leurs méthodes d'utilisation
CN113365639A (zh) * 2018-06-27 2021-09-07 摩登纳特斯有限公司 个性化癌症疫苗表位选择
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
WO2020097291A1 (fr) * 2018-11-07 2020-05-14 Modernatx, Inc. Vaccins à arn contre le cancer
CA3114265A1 (fr) * 2018-11-15 2020-05-22 Nouscom Ag Selection de mutations de cancer pour la generation d'un vaccin personnalise contre le cancer
KR20210127924A (ko) * 2019-01-04 2021-10-25 레퍼토리 아임뮨 메디신스, 인크. 고다양성 펩티드 라이브러리의 제조 및 단백질 폴딩의 촉진 방법
JOP20210186A1 (ar) * 2019-01-10 2023-01-30 Janssen Biotech Inc مستضدات البروستاتا المستحدثة واستخداماتها
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
JP2022521094A (ja) 2019-02-20 2022-04-05 モデルナティエックス インコーポレイテッド 共転写キャッピング用rnaポリメラーゼバリアント
AU2020234003A1 (en) * 2019-03-11 2021-11-11 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
WO2020190750A1 (fr) 2019-03-15 2020-09-24 Modernatx, Inc. Vaccins à base d'arn contre le vih
US12018289B2 (en) 2019-11-18 2024-06-25 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2021123232A1 (fr) * 2019-12-18 2021-06-24 Evaxion Biotech Aps Vaccination par acides nucléiques au moyen de constructions codant pour des néo-épitopes
CA3174215A1 (fr) 2020-04-22 2021-10-28 Ugur Sahin Vaccin contre un coronavirus
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
GB202017119D0 (en) * 2020-10-28 2020-12-09 Oxford Vacmedix Uk Ltd Polypeptides for cancer treatment
WO2022120560A1 (fr) * 2020-12-08 2022-06-16 深圳市瑞吉生物科技有限公司 Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs
JP2024506629A (ja) * 2021-02-09 2024-02-14 バージニア コモンウェルス ユニバーシティー mini環状RNA治療薬及びワクチン、並びにそれらの使用方法
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2023161350A1 (fr) 2022-02-24 2023-08-31 Io Biotech Aps Administration nucléotidique d'une thérapie anticancéreuse
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
GB202216449D0 (en) 2022-11-04 2022-12-21 Io Biotech Aps TGF-BETA1 vaccine
WO2024102764A1 (fr) * 2022-11-07 2024-05-16 The Wistar Institute Of Anatomy And Biology Compositions contenant des néo-antigènes et méthodes d'amélioration de la thérapie anti-pd1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569633B1 (fr) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions et procédés d'identification de néoantigènes spécifiques à une tumeur
DK2714071T3 (da) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
SG10201602456WA (en) 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
RS63244B1 (sr) * 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2016128060A1 (fr) * 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination

Also Published As

Publication number Publication date
WO2017020026A1 (fr) 2017-02-02
US20190008938A1 (en) 2019-01-10
EP3328394A4 (fr) 2019-03-13
EP3328394A1 (fr) 2018-06-06
US20220152178A1 (en) 2022-05-19
HK1256498A1 (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
MA42543A (fr) Arn épitope peptidiques concatémériques
MA44479A (fr) Arn transrepliquant
MA47680A (fr) Arn thérapeutique
DK3393510T3 (da) Zikavirusvaccine
DK3197453T3 (da) Kimært protein
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3099791T3 (da) Protein
DK3184642T3 (da) Gærcelle
DK3099793T3 (da) Protein
DK3359083T3 (da) Tandbørste
GB201616904D0 (en) Vaccine
NO3050465T3 (no) Seating
DK3157561T3 (da) Forbedrede alpha-v beta-8 antistoffer
DE112016001950A5 (de) Sitzgruppe
FI20170119A (fi) Istuin
ES2775740T8 (es) Péptidos
UA36457S (uk) Песарій кільцеподібний
UA33364S (uk) Стілець
UA33259S (uk) Стілець
FI11433U1 (fi) Postilaatikko
UA32920S (uk) Стілець
FI20165227A (fi) Ohjattava vastakkain-pyörivä potkurijärjestely
UA31285S (uk) Стілець
UA30915S (uk) Стілець
GB201603029D0 (en) Vaccine